Skip to content
Screener

Mesa Laboratories MLAB Q3 2026 earnings

Reported February 3, 2026 · Before market open

Revenue$65.1MBeat by $1.9M
EPS$3.07Beat by $1.67
Revenue estimate$63.2M
EPS estimate$1.40

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$61.6M
EPS estimate$1.59

Financials

Q3 2026

Income statement

See full
Revenue$65.1M+3.6%
Net income$3.6M+317%

Balance sheet

See full
Cash & equivalents$29.0M+6.1%
Total debt$66.6M-60.3%
Total equity$186.7M+20.3%
Total assets$434.8M+0.3%

Cash flow

See full
Operating cash flow$18.8M+3.4%
CapEx$732.0K-10.0%
Free cash flow$18.0M+4.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$433.5M-39.5%
Enterprise value$471.14M-45.0%
P/E116.1×—
P/S1.8×-1.3×

Profitability

See full
Net margin1.5%+0.8pp
FCF margin15.3%-2.8pp

Returns & leverage

See full
Return on equity2.2%+1.1pp
Debt / equity0.4×-0.7×
Current ratio1.9×+1.3×

Segments

By geography

See full
US$29.9M-1.9%
Other$29.6M+13.6%
CN$5.6M-10.7%

By segment

See full
Biopharmaceutical Development$14.4M—
Clinical Genomics$11.8M—

By product

See full
Consumables$36.7M—
Hardware And Software$17.3M—

FAQ

When did Mesa Laboratories report Q3 2026 earnings?
Mesa Laboratories (MLAB) reported Q3 2026 earnings on February 3, 2026 before market open.
What were Mesa Laboratories's Q3 2026 revenue and EPS?
Mesa Laboratories reported revenue of $65.1M and eps of $3.07 for Q3 2026.
Did Mesa Laboratories beat estimates in Q3 2026?
Revenue beat the consensus estimate of $63.2M by $1.9M. EPS beat the consensus estimate of $1.40 by $1.67.
How did Mesa Laboratories's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 3.6% from $62.8M a year earlier and eps grew 15.0% from $2.67.
Where can I find Mesa Laboratories's Q3 2026 SEC filings?
You can read the 8-K earnings release (0000724004-26-000015) and the 10-Q periodic report (0000724004-26-000016) directly on SEC EDGAR. The filing index links above go to sec.gov.